Trial Profile
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2020
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary) ; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Regeneron Pharmaceuticals
- 29 Jul 2020 Results assessing pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships of sarilumab versus tocilizumab in rheumatoid arthritis patients, published in the Journal of Clinical Pharmacology.
- 19 Dec 2018 Results assessing the safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis in the ASCERTAIN and Study 1309, published in the Rheumatology
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development